Commodity
MEDIUMTrigger: Wood pulp prices are driven by global paper/pulp supply-demand dynamics, which are outside Accent Microcell's control — making this a persistent earnings volatility driver
Monitor: commodity
In , Accent Microcell Ltd (Pharma - Formulators) is outperforming Nifty 500 with +43.8% relative strength. Fundamentals: Average. On a 12-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Earnings deceleration risks from management commentary
Trigger: Wood pulp prices are driven by global paper/pulp supply-demand dynamics, which are outside Accent Microcell's control — making this a persistent earnings volatility driver
Monitor: commodity
Trigger: INR appreciation of even 3-5% could compress PAT by 1.5-2% given the revenue exposure, which is material for a company with 17% OPM
Monitor: fx
Trigger: Expanding into regulated markets increases the compliance surface area — a US FDA audit is the key gating event for US market revenue growth
Monitor: regulatory
Key quotes from recent conference calls
“Commodity price risk remains central, as the company is sensitive to the cost of wood pulp and alpha cellulose [Risk (commodity): MEDIUM]”
“Foreign exchange risk is also active given that 45% of revenue is derived from exports, making the bottom line vulnerable to Rupee appreciation [Risk (fx): MEDIUM]”
“Targeting further penetration in regulated markets — shift toward high-purity MCC grades expected to support margin improvement [Risk (regulatory): LOW]”
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +10% | +17% | Stable |
| PAT (Net Profit) | +13% | +77% | Stable |
| OPM | 17.0% | +200 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Accent Microcell Ltd's latest quarterly results (Sep 2025) show
Accent Microcell Ltd's profit is growing with an stable trend.
Accent Microcell Ltd's revenue growth trend is stable.
Accent Microcell Ltd's operating margin is stable.
Accent Microcell Ltd's long-term compounding rates
Accent Microcell Ltd's earnings growth is stable with mixed signals on a sequential basis.
Accent Microcell Ltd appears significantly undervalued based on our fair value analysis.
Accent Microcell Ltd's current PE ratio is 32.5x.
Accent Microcell Ltd's current PE is 32.5x.
Accent Microcell Ltd's price-to-book ratio is 4.5x.
Accent Microcell Ltd is rated Average with a fundamental score of 58.5/100. This score is calculated from objective financial metrics
Accent Microcell Ltd has a debt-to-equity ratio of N/A.
Accent Microcell Ltd's return ratios over recent years
Accent Microcell Ltd's operating cash flow is positive (FY2025).
Accent Microcell Ltd's current dividend yield is 0.21%.
Accent Microcell Ltd's shareholding pattern (Mar 2026)
Accent Microcell Ltd's promoter holding has increased recently.
Accent Microcell Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Accent Microcell Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
Accent Microcell Ltd has 3 key risks worth monitoring
In Q2 FY26, Accent Microcell Ltd's management highlighted
Based on quantitative research signals, here is why Accent Microcell Ltd may be worth studying
Accent Microcell Ltd investment thesis summary:
Accent Microcell Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.